Skip to content
drillr.ai
Sign up

688091.SH

上海谊众

SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

CNY 36.96
−7.65%
Ask drillr

  • Aug 25, 2026, 08:16 UTC

    Shanghai Yizhong announced its H1 2026 results: revenue of 166 million yuan, up 3.45% year-on-year; net profit attributable to shareholders of 42.3036 million yuan, up 11.31% year-on-year.

    Source:

  • Aug 18, 2026, 11:12 UTC

    Shanghai Yizhong received approval from China's National Medical Products Administration for the clinical trial of its investigational drug YXC-002 for non-small cell lung cancer.

    Source:

  • Aug 17, 2026, 08:54 UTC

    Shanghai Yizhong's wholly-owned subsidiary Shanghai Youxi Chuang Pharmaceutical Technology received a drug clinical trial approval notice from China's National Medical Products Administration for its self-developed innovative drug YXC-001 (a trifunctional antibody fusion protein) for the treatment of advanced solid tumors.

    Source: